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Objective: This study was designed to evaluate the short-term efﬁcacy and safety of once-daily lurasidone
(80 mg/day and 160 mg/day) in the treatment of an acute exacerbation of schizophrenia.
Methods: Participants, who were recently admitted inpatients with schizophrenia with an acute exacerbation
of psychotic symptoms, were randomly assigned to 6 weeks of ﬁxed-dose, double-blind treatment with
lurasidone 80 mg (n=125), lurasidone 160 mg (n=121), quetiapine XR 600 mg (QXR-600 mg; n=119;
active control included to test for assay sensitivity), or placebo (n=121), all dosed once daily in the evening.
Efﬁcacy was evaluated using a mixed-model repeated-measures analysis of the change from Baseline
to Week 6 in Positive and Negative Syndrome Scale (PANSS) total score (the primary efﬁcacy measure)
and Clinical Global Impressions severity (CGI-S) score (the key secondary efﬁcacy measure).
Results: Treatment with both doses of lurasidone or with QXR-600 mg was associated with signiﬁcantly
greater improvement at Week 6 on PANSS total score, PANSS positive and negative subscale scores, and
CGI-S score compared with placebo. The endpoint responder rate (≥20% improvement in PANSS total
score) was higher in subjects treated with lurasidone 80 mg (65%; pb0.001), lurasidone 160 mg (79%;
pb0.001), and QXR-600 mg (79%; pb0.001) compared with placebo (41%). The proportion of patients
experiencing ≥7% weight gain was 4% for each lurasidone group, 15% for the QXR-600 mg group, and 3%
for the placebo group. Endpoint changes in levels of cholesterol, triglycerides, and low-density lipoprotein
(LDL) cholesterol were comparable for both lurasidone groups and placebo, while the QXR-600 mg group
showed a signiﬁcant median increase compared with the placebo group in levels of cholesterol (pb0.001),
LDL cholesterol (pb0.01), and triglycerides (pb0.05).
Conclusions: Lurasidone 80 mg and 160 mg doses administered once-daily in the evening, were safe and
effective treatments for subjects with acute schizophrenia, with increased response rates observed at the
higher dose. Dose-related adverse effects were limited, and both doses were generally well-tolerated.© 2013 Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
Lurasidone hydrochloride (HCl) is a novel benzisothiazol deriva-
tive that has recently been approved by the FDA for the treatment of
schizophrenia. Lurasidone has potent binding afﬁnity for D2, 5-HT2A
and 5HT7 receptors (antagonist effect), moderate afﬁnity for 5HT1Aave been previously presented
harmacology, Miami Beach, FL,
erican Psychiatric Association,
nd Human Behavior, University
ne, CA 92617, USA. Tel.:+1 949
-NC-ND license.(partial agonist effect) and α2C receptors (antagonist effect), and no
appreciable afﬁnity for H1 and M1 receptors (Ishibashi et al., 2010).
The efﬁcacy of lurasidone, in once-daily doses ranging from 40
to 120 mg, in the treatment of acute exacerbations of schizophrenia
has been demonstrated in previous double-blind, placebo-controlled
studies (Nakamura et al., 2009; Citrome, 2011; Meltzer et al., 2011;
Ogasa et al., 2013). Since lurasidone doses above 120 mg/d have not
been previously studied in any placebo-controlled clinical trial, it is
unclear whether doses above 120 mg/d have utility in the treatment
of schizophrenia.
Empirically establishing the full therapeutic dosing range for new
antipsychotic agents has proven to be challenging. Examination of
atypical antipsychotic dosing patterns over time suggests that dose
ranges ultimately judged to be optimal in the “real world” may differ
from initial recommendations based on the results of registration
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Citrome et al., 2009). Although the speciﬁc reasons for such gradual
evolution in dosage patterns are not clear, clinical trials may include
subjects with somewhat less diagnostic heterogeneity, comorbidity
and illness severity than patients encountered in clinical practice
settings (Seeman, 2001). In addition, since D2 receptor occupancy
rates show a signiﬁcant degree of inter-individual variability at a
given dose (Kapur et al., 2000; Mamo et al., 2004; Catafau et al.,
2009), higher daily doses may be required in some patients to ensure
that adequate steady-state plasma and CNS concentrations are reached.
From a practical standpoint, dose escalation is one of the most fre-
quently used treatment strategies for patients with more severe illness
and those who do not respond to initial treatment at lower therapeutic
doses (Kinon et al., 2004; Schwartz and Stahl, 2011).
This is the ﬁrst placebo-controlled trial to evaluate the efﬁcacy and
safety of treatment with lurasidone 160 mg/d, a dose above the previ-
ously established therapeutic range. The study utilized a ﬁxed-dose
design that included a lurasidone 80 mg arm (to permit assessment
of dose–response effects) and a quetiapine XR arm (QXR-600 mg),
to establish assay sensitivity.
2. Methods
This was a multiregional, prospective, parallel-group study in which
subjects with a primary diagnosis of schizophrenia, who had been re-
cently hospitalized for an acute exacerbation of psychotic symptoms,
were randomly assigned to receive 6 weeks of double-blind treatment
with once-daily evening doses of lurasidone (80 mg, 160 mg), QXR
(600 mg), or placebo. The study was conducted between October 21,
2008, and June 2, 2010, enrolling a total of 486 subjects at 24 centers
in the United States (n=151 subjects), 10 centers in Russia (n=87),
10 centers in India (n=98), 9 centers in Ukraine (n=75), 6 centers
in Romania (n=49), and 4 centers in Colombia (n=26). Subjects
who successfully completed this 6-week trial were eligible for enroll-
ment in a 12-month double-blind extension study.
All subjects who entered the trial reviewed and provided informed
consent. The study protocol was approved by an independent ethics
committee associated with each study center. The studywas conducted
in accordance with the International Conference on Harmonization
Good Clinical Practices guidelines and with the ethical principles of
the Declaration of Helsinki. An independent data and safety monitoring
board reviewed safety and clinical outcome data at regular intervals
during the study.
2.1. Entry criteria
Hospitalizedmale and female subjects 18–75 years of age, inclusive,
whomet DSM-IV-TR criteria for a primary diagnosis of schizophrenia as
determined by clinical interview using the Mini International Neuro-
psychiatric InterviewPlus (Sheehan et al., 1998)were enrolled. Subjects
were also required to have an illness duration greater than 1 year with
the current acute exacerbation of psychotic symptoms no longer than
2 months and, at the Screening and Baseline visits, to have a Clinical
Global Impression, Severity (CGI-S) score ≥4 (moderate or greater)
and a Positive and Negative Syndrome Scale (PANSS) total score ≥80,
including a score ≥4 (moderate) on two or more of the following
PANSS items: delusions, conceptual disorganization, hallucinations,
unusual thought content, and suspiciousness.
2.2. Study medication
All study medication was identically overencapsulated to preserve
the double-blind. After completing a Screening period (≤14 days)
during which they were tapered off psychotropic medication, sub-
jects completed a 3- to 7-day placebo washout period. At Baseline
(day 0), subjects were randomly assigned (in a 1:1:1:1 ratio) via aninteractive voice response system to one of four treatment arms:
lurasidone, 80 mg/day; lurasidone, 160 mg/day; QXR, 600 mg/day;
or placebo. Study medication was administered in the evening with
a meal or within 30 min after eating. Subjects assigned to lurasidone
80 mg/day started treatment at their target dose. Subjects assigned to
lurasidone 160 mg/day started treatment at a dose of 120 mg/day for
2 days before being increased to their target dose. Subjects assigned
to QXR 600 mg/day were started at a dose of 300 mg/day for 2 days
before being increased to their target dose (consistent with manufac-
turer recommendations). The QXR dosage of 600 mg/daywas selected
because it has been established as an effective dose in the middle
of the approved dosing range for the treatment of patients with
schizophrenia (Seroquel XR USPI), and because there does not appear
to be a signiﬁcant efﬁcacy advantagewhen using the highest approved
800 mg dose (Kahn et al., 2007; Lindenmayer et al., 2011; Zhornitsky
et al., 2011).
Subjects were eligible for hospital discharge after completing
21 days of double-blind treatment if theymet speciﬁc clinical stability
criteria.
2.3. Assessments
The screening evaluation consisted of the Mini International Neu-
ropsychiatric Interview Plus (Sheehan et al., 1998), medical and psy-
chiatric histories, a physical examination, measurement of vital signs,
ECG, and laboratory tests. Efﬁcacy was assessed using the PANSS
total and subscale scores (Kay et al., 1987; Marder et al., 1997), the
CGI-S (Guy, 1976), the Montgomery–Åsberg Depression Rating Scale
(MADRS; Montgomery and Åsberg, 1979), the Negative Symptom
Assessment Scale (NSA-16; Axelrod et al., 1993), an interviewer admin-
istered version of the Quality of Well-being Scale (QWB-SA; Kaplan
et al., 1998); and the single-item, subject-rated Medication Satisfaction
Questionnaire (MSQ; Vernon et al., 2010). The subject-rated, 8-item
Epworth Sleepiness Scale was administered at Baseline, and Weeks 3
and 6 to evaluate the level of daytime sleepiness.
Safety evaluations included vital signs, weight, body mass index,
waist circumference, laboratory tests (including lipids, glucose,
glycosylated hemoglobin [HbA1c], insulin, and prolactin, C-reactive
protein), 12-lead ECG, and subject-reported adverse events. Extrapy-
ramidal symptoms were assessed with the Simpson-Angus Rating
Scale (Simpson and Angus, 1970), the Barnes Rating Scale for Drug-
Induced Akathisia (Barnes, 1989), and the Abnormal Involuntary
Movement Scale (Guy, 1976).
The present study also included an assessment of the effects of
treatment on cognitive function using a computerized cognitive bat-
tery (CogState; Pietrzak et al., 2009). Cognitive assessment ﬁndings
from this study will be reported elsewhere (Harvey et al., 2011).
2.4. Statistical methods
The study was powered at 97.5% to detect an 8-point difference
with a pooled standard deviation of 19 between lurasidone and place-
bo in Week 6 change-from-baseline in PANSS total scores and reject
the null hypothesis of no difference from placebo in at least one
lurasidone dose at an α-level of 0.05 based on a 2-sided test.
The primary efﬁcacymeasure was the change from Baseline in PANSS
total score at Week 6, and the key secondary efﬁcacy measure was the
change from Baseline in CGI-S score at Week 6. Both measures were
evaluated by a mixed-model repeated-measures (MMRM) analysis with
an unstructured covariancematrix, as used in a previously reported clini-
cal trial (Meltzer et al., 2011). The p-values for the comparison of each
lurasidone group with the placebo group at Week 6 on changes from
Baseline in PANSS total score and in CGI-S score were adjusted for multi-
ple comparisons using the Hommel-based tree-gatekeeping procedure.
The QXR-600 mg treatment group was compared with placebo using
the same mixed-model repeated measures model, without adjustment
Table 1
Baseline characteristics of subjects randomized to treatment with lurasidone, quetiapine
XR or placebo — safety population.
Characteristic Treatment group
Lurasidone
80 mg/d
(N=125)
Lurasidone
160 mg/d
(N=121)
Quetiapine
XR 600 mg/d
(N=119)
Placebo
(N=121)
n % N % n % n %
Male 96 77 82 68 77 65 77 64
Race
White 75 60 63 52 69 58 68 56
Black
Asian
22
24
18
19
29
25
24
21
19
26
16
22
25
24
21
20
Other 4 3 4 3 5 4 4 3
Ethnicity, Hispanic/Latino 10 8 8 7 10 8 10 8
Prior hospitalizations: ≥4 64 51 63 52 55 46 58 48
Mean SD Mean SD Mean SD Mean SD
Age, years 36.2 10.9 37.9 11.3 37.4 10.4 37.4 10.8
Age at onset of illness,
years
24.6 8.3 25.7 7.8 24.5 8.6 25.5 8.6
Duration of illness, years 11.1 9.2 11.8 8.8 12.4 10.4 11.3 9.3
Duration of current
episode, days
31.3 12.9 31.7 12.7 31.5 13.6 32.6 14.3
PANSS total score a 97.7 9.7 97.5 11.8 97.7 10.2 96.6 10.2
CGI-severity a 5.0 0.5 5.0 0.6 4.9 0.6 4.9 0.5
MADRS total score a 11.6 7.6 11.2 7.8 12.3 8.1 11.3 6.7
a Data for these parameters are based on the intent-to-treat population.
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analysis was also conducted for change in PANSS total score and CGI-S
score at Week 6 LOCF endpoint, using an analysis of covariance
(ANCOVA) model, with effects for Baseline score, pooled center, and
treatment.
The PANSS responder rates (deﬁned a priori as ≥20% improve-
ment in PANSS total score) were evaluated with logistic regression
using responder outcome as the dependent variable, treatment as a
categorical factor, and Baseline PANSS total score as a covariate.
The PANSS subscores and symptom factor scores were evaluated
using MMRM and a supportive ANCOVA. MADRS, NSA-16, and QWB-SA
were evaluated using ANCOVA. Therewas no adjustment for multiplicity
for these parameters.
Signiﬁcance testing of safety parameters was performed based on
a nonparametric rank ANCOVA with Baseline value as a covariate, not
adjusted for multiple comparisons.
3. Results
A total of 668 subjects were screened and entered the washout
period, of whom 488 were randomly assigned to 6 weeks of double-
blind treatment (Fig. 1). Baseline demographic and clinical character-
istics were comparable among the four treatment groups and similar
to previously reported from other trials (Table 1). Greater than 70% of
subjects completed study treatment in the lurasidone 80 mg (71.2%)
and 160 mg groups (76.9%), and the QXR-600 mg group (80.8%),
while a lower proportion of subjects in the placebo group completed
treatment (60.7%; Fig. 1).
3.1. Efﬁcacy
Using amixed-model repeated-measures analysis, LSmean change
(SE) from Baseline to Week 6 in PANSS total score was found to be
signiﬁcantly greater for the lurasidone 80 mg (−22.2 [1.8]; adjusted
pb0.001) and 160 mg (−26.5 [1.8]; adjusted pb0.001) groups com-
pared with the placebo group (−10.3 [1.8]) (Table 2). The LS mean
change (SE) from Baseline to Week 6 in PANSS total score was also
signiﬁcantly greater for the QXR-600 mg group vs. placebo (−27.8
[1.8], pb0.001), thus conﬁrming the assay sensitivity of the study.
LS mean change from Baseline in the PANSS total score was similar
for lurasidone 160 mg vs. QXR-600 mg (−26.5 vs.−27.8; unadjusted
p=0.62; Bonferroni corrected p=1.00), however, this change wasFig. 1. Flow diagram andgreater with QXR-600 mg compared with lurasidone 80 mg (−27.8
vs.−22.2; unadjusted for multiple comparisons, p=0.028; Bonferroni
corrected, p=0.056).
Statistically signiﬁcant separation from placebo (−2.4 [0.5]) on
the PANSS total score was observed by Day 4 in the lurasidone
80 mg (−4.1 [0.5]; p=0.014) and 160 mg (−4.8 [0.5]; pb0.001)
groups, and in the QXR-600 mg group (−4.0 [0.5]; p=0.028). Signif-
icant separation from placebo was also observed at each subsequent
assessment week for each of the three study treatments (Fig. 2).
For the key secondary efﬁcacy measure, the CGI-S, the LS mean
change score from Baseline to Week 6 was signiﬁcantly greater for
both lurasidone treatment groups, and for QXR-600 mg, compared
with the placebo group (Table 2).
A pairwise comparison of improvement at Week 6 (using MMRM)
found trend level differences in favor of the 160 mg dose comparedsubject disposition.
Table 2
Change from baseline to week 6 on efﬁcacy measures for patients with schizophrenia in a randomized, double-blind, placebo- and quetiapine XR-controlled study of lurasidone –
intent-to-treat population.
Measure a Treatment group
Lurasidone 80 mg/d
(N=125)
Lurasidone 160 mg/d
(N=121)
Quetiapine XR 600 mg/d
(N=116)
Placebo (N=120)
Estimate SE Estimate SE Estimate SE Estimate SE
PANSSb
Total score change −22.2*** 1.8 −26.5*** 1.8 −27.8*** 1.8 −10.3 1.8
Positive subscale score change −7.7*** 0.6 −9.2*** 0.6 −9.7*** 0.6 −3.9 0.6
Negative subscale score change −5.1*** 0.4 −5.5*** 0.4 −5.4*** 0.4 −2.2 0.5
General psychopathology subscale score change −10.0*** 0.8 −12.3*** 0.8 −12.9*** 0.8 −5.0 0.9
CGI-Severity score change b −1.5*** 0.1 −1.7*** 0.1 −1.7*** 0.1 −0.9 0.1
NSA-16 total score change c −7.8*** 0.8 −8.9*** 0.8 −8.6*** 0.8 −3.4 0.8
MADRS total score change c −4.0*** 0.5 −4.4*** 0.5 −4.3*** 0.5 −1.0 0.5
Quality of well-being (SA) c +0.67* 0.02 +0.71*** 0.02 +0.71*** 0.02 +0.63 0.02
Medication satisfaction questionnaire c +1.5*** 0.1 +1.6*** 0.2 +1.8*** 0.2 +0.7 0.2
*Pb0.05; **Pb0.01; ***Pb0.001.
a Endpoint change scores are shown for all measures except the QWB-SA. PANSS: positive and negative symptom scale; CGI: clinical global impression scale; MADRS:
Montgomery-Äsberg Depression Rating Scale; NSA-16: Negative Symptom Assessment Scale.
b p-values, comparing drug to placebo, are based on a repeated measures linear regression model of the change from Baseline score, with ﬁxed effects for pooled center, visit as a
categorical variable, Baseline score, treatment and treatment by visit interaction, assuming an unstructured covariance matrix.
c p-values are based on an ANCOVA at Week 6 LOCF endpoint with treatment and pooled center as ﬁxed factors and Baseline value as a covariate.
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and the CGI-S score (p=0.057). For LOCF-endpoint change in the
PANSS total score, the Cohen's d effect size was 0.58 for lurasidone
80 mg compared to 0.83 for lurasidone 160 mg; and for the CGI-S
score, the Cohen's d effect sizewas 0.54 for lurasidone 80 mg compared
to 0.81 for lurasidone 160 mg. The ANCOVA subgroup analyses showed
no signiﬁcant treatment interactions by gender, race, ethnicity, region,
or age for either the PANSS total score or the CGI-S score.
Treatment with both doses of lurasidone and QXR-600 mg were
associated with signiﬁcantly greater Week 6 improvement, compared
with placebo, in the PANSS positive and negative subscores (Table 2).
Week 6 improvement in the NSA-16 scale was also signiﬁcant for
both doses of lurasidone and for QXR-600 mg (Table 2) compared
with placebo.
The proportion of responders (≥20% improvement in PANSS total
score from Baseline to LOCF-endpoint) was higher in subjects treated
with lurasidone 80 mg (65%; pb0.001) and lurasidone 160 mg (79%;
pb0.001) compared with subjects treated with placebo (41%). The
proportion of responders was also higher for QXR-600 mg (79% vs.Fig. 2. Change from baseline in PANSS total score — mixed model repeated measurements
based on a repeated measures linear regression model of the change from Baseline score, wit
and treatment by visit interaction, assuming an unstructured covariance matrix. Compar
160 mg; p=0.028 for quetiapine XR. b Week 1: pb0.001 for lurasidone 80 mg and 160 m
for quetiapine XR. d Week 3: pb0.001 for lurasidone 80 mg and 160 mg, and for quetiap
f Week 5: pb0.001 for lurasidone 80 mg and 160 mg, and for quetiapine XR. g Week 6: pbplacebo, 41%; pb0.001). The responder rate was signiﬁcantly higher
for the 160 mg dose of lurasidone compared with the 80 mg dose
(p=0.018), with an NNT of 8 (95%-CI, 5, 39).
Treatment with both doses of lurasidone and QXR-600 mg were
associated with signiﬁcantly greater Week 6 improvement in depres-
sive symptoms assessed using the MADRS compared with the placebo
group (Table 2); and signiﬁcantly greater improvement in both the
quality of well-being self-assessment (QWB-SA) scale, and the medi-
cation satisfaction questionnaire compared with the placebo group
(MSQ; Table 2).
3.2. Safety
3.2.1. Body weight, body mass index (BMI), and waist circumference
Treatment with lurasidone 80 mg was associated with a small
but signiﬁcant increase in weight and BMI when compared with pla-
cebo, while changes in weight, BMI, and waist circumference were
similar for the lurasidone 160 mg and placebo groups (Table 3).
Clinically signiﬁcant (≥7%) increase in weight was reported by aanalysis (MMRM. Intent-to-treat population). LS means and p-values were computed
h ﬁxed effects for pooled center, visit as a categorical variable, baseline score, treatment
isons with placebo: a Day 4: p=0.014 for lurasidone 80 mg; pb0.001 for lurasidone
g, and for quetiapine XR. c Week 2: pb0.001 for lurasidone 80 mg and 160 mg, and
ine XR. e Week 4: pb0.001 for lurasidone 80 mg and 160 mg, and for quetiapine XR.
0.001 for lurasidone 80 mg and 160 mg, and for quetiapine XR.
Table 3
Effect of 6 weeks of treatment with lurasidone, quetiapine XR, or placebo on weight, body mass index, waist circumference, and laboratory test results (week 6 LOCF-endpoint
analysis, safety population).a
Measure Treatment group
Lurasidone 80 mg/d Lurasidone 160 mg/d Quetiapine XR 600 mg/d Placebo
n Value n Value n Value n Value
Weight, kg, mean (SD)
Baseline 125 76.1 (17.3) 121 74.4 (17.2) 119 72.1 (17.0) 121 75.85 (16.3)
Change 116 +0.6 (2.6)* 113 +0.6 (3.1) 111 +2.1 (3.3)*** 115 +0.1 (2.5)
≥7% increase in weight, n (%)
Week 6 116 5 (4.3) 113 5 (4.4) 111 17 (15.3) 115 3 (2.6)
Body mass index, kg/m2, mean (SD)
Baseline 125 25.7 (4.95) 121 25.6 (4.85) 119 25.5 (5.2) 121 26.1 (4.8)
Change 116 +0.2 (0.85)* 113 +0.2 (1.0) 111 +0.7 (1.1)*** 115 +0.0 (0.8)
Waist circumference, cm, mean (SD)
Baseline 125 88.3 (13.2) 121 87.0 (14.25) 119 87.35 (14.5) 121 88.4 (13.0)
Change 115 +0.9 (3.0) 110 +1.3 (3.8) 111 +1.8 (5.2) 115 +0.2 (3.0)
Total cholesterol, mg/dL, median
Baseline 125 180.0 121 188.0 119 186.0 121 184.0
Change 111 −4.0 114 −7.5 107 +6.0*** 111 −7.0
LDL cholesterol, mg/dL, median
Baseline 125 107.0 121 112.0 119 111.0 121 111.0
Change 111 −3.0 114 −4.0 107 +4.0** 111 −3.0
HDL cholesterol, mg/dL, median
Baseline 125 43.0 121 43.0 119 42.0 121 42.0
Change 111 0.0* 114 0.0 107 0.0* 111 −3.0
Triglycerides (mg/dL)
Baseline 125 106.0 121 110.0 119 115.0 121 102.0
Change 111 −2.0 114 −9.0 106 +8.0* 111 −9.0
Glucose, mg/dL, median
Baseline 125 92.0 121 90.0 119 91.0 121 93.0
Change 111 −1.0 112 0.0 107 +3.0 110 0.0
HbA1c, mean % (SD)
Baseline 125 5.4 (0.4) 121 5.5 (0.45) 119 5.5 (0.5) 121 5.5 (0.4)
Change 109 +0.1 (0.4) 111 0.01 (0.28) 104 0.03 (0.31) 108 0.01 (0.30)
Insulin, mU/L, median
Baseline 120 8.8 121 9.0 116 8.7 118 9.0
Change 106 −0.4 114 +0.5 104 +0.4 109 −0.3
Prolactin, ng/mL, median
Baseline 125 7.5 121 8.6 119 8.7 121 10.1
Change 111 +0.8 114 +3.0*** 107 −0.3 111 −0.8
* pb0.05; ** pb0.01; *** pb0.001.
Comparisons of the lurasidone and quetiapine XR groups vs. placebo at LOCF Endpoint are based on a rank ANCOVA analysis. Signiﬁcance testing was not performed for waist
circumference, HbA1c, and insulin.
a HbA1c=glycated hemoglobin; LDL=low-density lipoprotein; HDL=high-density lipoprotein.
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and 160 mg (n=5; 4%) groups, and the placebo group (n=3; 3%). In
contrast, there was a signiﬁcant mean increase in the QXR-600 mg
group compared with the placebo group in both weight and BMI
(Table 3), with 17 subjects (15%) having a clinically signiﬁcant weight
gain.
3.2.2. Metabolic parameters
Changes in lipid levels were comparable for both lurasidone dosage
groups and the placebo group, while the QXR-600 mg group showed
a signiﬁcant median increase compared with the placebo group in
levels of cholesterol, LDL, and triglycerides (pb0.05, LOCF-endpoint;
Table 3). Changes in glucose and insulin were also comparable for
both lurasidone groups, and the QXR-600 mg and placebo groups
(Table 3). There were no clinically relevant changes in HbA1c values
for any treatment group, and no endpoint differences for the lurasidone
and QXR-600 mg treatment groups compared with placebo.
Categorical shifts from normal to high (abnormal) values for lipid
and glucose parameters were as follows: total cholesterol (lurasidone
80 mg, 7.2%; lurasidone 160 mg, 5.3%; QXR-600 mg, 15.9%; placebo,
6.3%), LDL cholesterol (lurasidone 80 mg, 7.2%; lurasidone 160 mg,
6.1%; QXR-600 mg, 15.0%; placebo, 4.5%), triglycerides (lurasidone
80 mg, 2.7%; lurasidone 160 mg, 5.3%; QXR-600 mg 10.4%; placebo,
6.3%), glucose (lurasidone 80 mg, 15.3%; lurasidone 160 mg, 18.8%;
QXR-600 mg, 26.2%; placebo 18.2%; Supplementary Table 1).3.2.3. Prolactin and other laboratory values
Median changes in prolactin levels at Week 6 (LOCF) were compa-
rable for the lurasidone 80 mg, QXR-600 mg and placebo groups, but
were signiﬁcantly higher for the lurasidone 160 mg group compared
with placebo (Table 3). Additional gender-speciﬁc information on
the effect of study treatment on prolactin is summarized in Supple-
mentary Table 1. No other clinically relevant differences were noted
for any other laboratory values when comparing either lurasidone
treatment group to the placebo group.
3.2.4. Physical examination and vital signs
Orthostatic hypotension (systolic) occurred in 3 of 246 subjects
(1.2%) in the combined lurasidone treatment groups, and in 4 of 17
subjects (3.4%) in the QXR-600 mg group; orthostatic tachycardia
occurred in 7 of 246 subjects (2.8%) in the combined lurasidone treat-
ment groups, and in 11 of 117 subjects (9.4%) in the QXR-600 mg
group. There were no other clinically signiﬁcant treatment-emergent
changes in either of the lurasidone groups, or the QXR-600 mg group,
compared with the placebo group, in physical examination ﬁndings
or vital signs.
3.2.5. ECG
Treatmentwith lurasidonewas not associatedwith any treatment-
emergent ECG abnormalities comparedwith placebo. Themean LOCF-
endpoint increase in the Bazett-corrected QT interval (QTcB) and
106 A. Loebel et al. / Schizophrenia Research 145 (2013) 101–109the Fridericia-corrected QT interval (QTcF), was 1.9 ms and 3.1 ms,
respectively, in the lurasidone 80 mg group, 3.9 ms and 2.8 ms in
the lurasidone 160 mg group, 10.4 ms and 3.0 ms in the quetiapine
XR group, and 7.6 ms and 6.1 ms in the placebo group. There was
no difference between the lurasidone 80 mg and 160 mg groups
and the placebo group in the proportion of subjects with an in-
crease from Baseline of ≥30 ms or ≥60 ms in QTc interval, either
QTcB or QTcF. No subject in any treatment group had a QTc interval
>500 ms.
3.2.6. Extrapyramidal symptoms and akathisia
The incidence of extrapyramidal-related adverse events was
11.2% in the lurasidone 80 mg group, 13.2% in the lurasidone
160 mg group, 5.9% in the QXR-600 mg group, and 0.8% in the place-
bo group (Supplementary Table 2). Parkinsonism was the most fre-
quently reported EPS-related event, reported by 5.6% of subjects
in the lurasidone 80 mg group, 6.6% of subjects in the lurasidone
160 mg group, 3.4% of subjects in the QXR-600 mg group, and no
subjects in the placebo group. The incidence of akathisia was 8.0%
in the lurasidone 80 mg group, 7.4% in the lurasidone 160 mg group,
1.7% in the QXR-600 mg group, and 0.8% in the placebo group
(Table 4). The effect of study treatment on movement disorder signs
or symptoms, as measured by change in SAS, BAS, and AIMS scores,
was generally absent to mild in subjects treated with lurasidone.
There were relatively small LS mean (±SE) changes at Week 6
(LOCF) in the BAS total score and SAS mean scores, respectively, in
subjects treated with lurasidone 80 mg (−0.1±0.1; −0.01±0.01)
and 160 mg (+0.1±0.1; 0.00±0.01), QXR-600 mg (−0.2±0.1;
−0.05±0.01), and placebo (−0.1±0.1; −0.03±0.01). Fewer than
5% of lurasidone-treated subjects showed a categorical shift at Week
6 (LOCF) from absent/mild to moderate-to-severe symptoms in any
BAS item. There were minimal-to-no changes from Baseline in the
AIMS total score for any treatment group.
The proportion of subjects receiving an as-needed anticholiner-
gic medication was 16% in the lurasidone 80 mg group, 17% in the
lurasidone 160 mg group, 9% in the QXR-600 mg group, and 0.8% in
the placebo group.
Discontinuations due to extrapyramidal adverse events occurred
in 0.8% of subjects in the lurasidone 80 mg group, 0.8% in the
lurasidone 160 mg group, 0.8% in the QXR-600 mg group, and no sub-
jects in the placebo group. Discontinuations due to akathisia occurred
in 1.6% of subjects in the lurasidone 80 mg group, 0.8% in the lurasidone
160 mg group, and in no subjects in the QXR-600 mg and placebo
groups.Table 4
Incidence of adverse events reported in ≥5% of subjects during 6 weeks of treatment with
Lurasidone 80 mg/d
(N=125)
Lurasido
(N=121
n % n
At least one adverse event 72 57.6 76
Headache 12 9.6 12
Insomnia 14 11.2 8
Akathisia 10 8.0 9
Nausea 10 8.0 8
Vomiting 8 6.4 9
Anxiety 9 7.2 4
Dizziness 6 4.8 7
Somnolence 5 4.0 8
Agitation 4 3.2 6
Dyspepsia 3 2.4 7
Constipation 3 2.4 1
Dry mouth 2 1.6 2
Arthralgia 2 1.6 1
Upper respiratory tract infection 2 1.6 1
Weight increased 1 0.8 2
Psychotic disorder 0 0 03.2.7. Epworth Sleepiness Scale (ESS)
At Baseline, the LS mean (±SE) ESS total scores were similar for
the lurasidone 80 mg (6.1±0.4) and 160 mg (6.3±0.4) groups, the
QXR-600 mg group (6.1±0.4), and the placebo group (6.4±0.4),
indicating a slight chance of dozing or sleeping during daytime hours.
At Week 6 (LOCF), treatment with lurasidone 80 mg and 160 mg, re-
spectively was associated with a similar decrease (i.e., improvement)
in LS mean (±SE) ESS total scores compared to placebo (−1.1±0.3
and−0.7±0.3 vs.−0.9±0.3; p>0.50 for both comparisons). In con-
trast, treatment with QXR-600 mgwas associated with a signiﬁcant in-
crease in the ESS total score compared with both placebo (+0.6±0.3
vs. −0.9±0.3; p=0.001), and with lurasidone 80 mg (pb0.001) and
160 mg (pb0.001).
3.2.8. Adverse events
A comparable proportion of subjects in the lurasidone, QXR-600 mg,
and placebo groups experienced at least one adverse event (Table 4).
The majority of adverse events in all treatment groups were rated
as mild to moderate. A similarly low proportion of subjects reported
at least one adverse event reported as “severe” on lurasidone 80 mg
(n=4; 3.2%), lurasidone 160 mg (n=4; 3.3%), QXR-600 mg (n=3;
2.5%) and placebo (n=7; 5.8%). Rates of discontinuations due to
adverse events were relatively low in the lurasidone 80 mg group
(4.0%), the lurasidone 160 mg group (3.3%), and the QXR-600 mg
group (3.3%) and were comparable to those in the placebo group
(4.1%). Adverse events that occurred with an incidence of at least 5%
are summarized in Table 4. No clear dose–response effect on the inci-
dence of adverse events was observed for lurasidone. There were no
treatment-emergent deaths during the study. Serious adverse events
are summarized in Supplementary Table 3.
4. Discussion
The results of this double-blind, placebo-controlled, multiregional
trial indicate that lurasidone, at ﬁxed dosages of 80 and 160 mg/d,
was an effective andwell-tolerated treatment for subjects experiencing
an acute exacerbation of chronic schizophrenia. These ﬁndings have
led to approval of the lurasidone in the dosing range of 40–160 mg/d
for the treatment of schizophrenia in the US and elsewhere (Latuda
USPI, 2012).
Treatment with lurasidone 160 mg/d was associated with a trend
to greater improvement on both the PANSS total and CGI-S scores
when compared with the 80 mg dose, which is reﬂected in the
Cohen's d effect size ﬁndings (0.83 vs. 0.58 for lurasidone 160 mg/dlurasidone, quetiapine XR, or placebo (safety population).
ne 160 mg/d
)
QuetiapineXR 600 mg/d
(N=119)
Placebo (N=121)
% n % n %
62.8 71 59.7 75 62.0
9.9 13 10.9 13 10.7
6.6 5 4.2 11 9.1
7.4 2 1.7 1 0.8
6.6 4 3.4 4 3.3
7.4 6 5.0 6 5.0
3.3 1 0.8 10 8.3
5.8 16 13.4 2 1.7
6.6 16 13.4 1 0.8
5.0 3 2.5 10 8.3
5.8 3 2.5 4 3.3
0.8 8 6.7 3 2.5
1.7 9 7.6 1 0.8
0.8 7 5.9 1 0.8
0.8 6 5.0 1 0.8
1.7 8 6.7 1 0.8
0 3 2.5 7 5.8
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signiﬁcantly higher endpoint responder rate compared to 80 mg/d
(79% vs. 65%, pb0.001). These ﬁndings contribute to a more complete
understanding of lurasidone dose–response in patients with schizo-
phrenia and provide an evidence base for use of higher lurasidone
doses where this is judged to be clinically appropriate.
The efﬁcacy advantage of the 160 mg dose of lurasidone was not
accompanied by a dose-related increase in the incidence or severity
of most adverse events compared with lurasidone 80 mg. In addition,
there were no between-dose differences in the discontinuation rate
due to adverse events (b5% in both lurasidone dosage groups), or
in the incidence of individual adverse events, or events rated as
“severe”. There were no clinically meaningful differences between
the 80 mg or 160 mg doses of lurasidone and placebo in effects
on weight, total cholesterol, LDL, triglycerides, insulin, glucose, or
HbA1c. The lack of a dose-relationship for weight and metabolic
effects in the current study is consistent with results from previous
ﬁxed-dose, placebo-controlled trials of lurasidone in the range of
40–120 mg/d (Nakamura et al., 2009; Meltzer et al., 2011), and ex-
tends these prior ﬁndings to the 160 mg/d dose. The minimal effect
of lurasidone on weight is consistent with pharmacology studies
indicating that lurasidone has no clinically relevant afﬁnity for recep-
tors hypothesized to be associated with weight gain: H1-histamine
(Ki, >1000) or 5-HT2C (Ki, 415; Kroeze et al., 2003; Ishibashi et al.,
2010; Correll et al., 2011). The apparent absence of a dose-related ef-
fect of lurasidone on weight and metabolic parameters differs from
dose-dependent effects reported for some other atypical antipsy-
chotics (clozapine, olanzapine, and possibly quetiapine; Simon et al.,
2009; de Hert et al., 2011). Treatment with lurasidone 160 mg/d,
compared with the 80 mg/d dose, was not associated with an in-
crease in discontinuations due to adverse events, or in the severity
of adverse events. Although akathisia frequency did not increase,
a small increase in frequency of EPS-related adverse events was
observed at the higher lurasidone dose. In addition, some increase
in the frequency of somnolence and dyspepsia was observed at the
higher lurasidone dose. We note that this was the ﬁrst lurasidone
placebo-controlled trial involving patients with schizophrenia where
study medication was administered (with food) in the evening. This
dosing strategy may in part account for the lower rate of adverse
events, including akathisia, compared to prior studies.
The low propensity of lurasidone for adverse effects on weight
and metabolic outcomes throughout its therapeutic dose range is
an important safety ﬁnding since schizophrenia, and its treatment,
is associated with a high degree of cardiometabolic risk that con-
tributes substantially to the excess mortality observed with the
illness (Osby et al., 2000; Goff et al., 2005; Saha et al., 2007). In a re-
cent meta-analysis, approximately one-third of patients diagnosed
with schizophrenia met criteria for metabolic syndrome (Mitchell et
al., 2012). Rates have been reported to be even higher in some patient
populations such as the CATIE schizophrenia study (41%; McEvoy et
al., 2005), in patients with longer illness durations, and in patients
who have been treated with atypical antipsychotics with established
adverse effects on weight and metabolic parameters, such as cloza-
pine and olanzapine (de Hert et al., 2011; Mitchell et al., 2012).
In this 6 week study, lurasidone was associated with a dose-related
increase in prolactin levels, primarily in female subjects, with the
80 mg/d dose showing an effect that was comparable with placebo,
while treatment with the 160 mg/d dose resulted in a greater median
increase comparedwith placebo (+3.0 vs.−0.8 ng/mL; LOCF). Change
in prolactin in the QXR-600 mg treatment group was comparable to
that of placebo.
Treatment with QXR-600 mg was associated with signiﬁcant end-
point improvement vs. placebo in the PANSS total score, CGI-S score,
and other secondary measures. The magnitude of improvement ob-
served for QXR-600 mg in the current study was comparable or greater
than that reported in previous placebo-controlled short-term trialswith both the IR and XR formulations (Kahn et al., 2007; Lindenmayer
et al., 2008; Baldwin and Scott, 2009). Therewas no difference between
QXR-600 mg and the 160 mg dose of lurasidone in change from Base-
line on the PANSS total score. Improvement in the PANSS total score
was signiﬁcantly greater for QXR-600 mg compared with lurasidone
80 mg, however this ﬁnding was of borderline signiﬁcance after
Bonferroni correction for multiplicity.
The frequency of adverse events in the QXR-600 mg group in the
current study was also consistent with results reported from previous
studies (Meulien et al., 2010). The most frequent adverse events
reported for QXR-600 mg were somnolence, orthostatic dizziness,
headache, weight gain, and anticholinergic-related events such as dry
mouth and constipation. Treatment with QXR-600 mg was associated
with a higher proportion of subjects with clinically meaningful weight
gain, and a higher proportion of subjects with clinically meaningful
increases in levels of total cholesterol, LDL, triglycerides, and glucose
than with lurasidone treatment. The effect of QXR-600 mg on weight
and metabolic parameters observed in the current study are consistent
with previous reports (Meulien et al., 2010; Rummel-Kluge et al., 2010).
In the present study, the incidence of orthostatic hypotension (3.4%)
and tachycardia (9.4%) were somewhat lower than rates reported in
previous short-term trials with QXR (Meulien et al., 2010).
Because somnolence is a signiﬁcant risk factor for nonadherence
and impairment in cognitive function and quality of life, a validated
measure, the Epworth Sleepiness Scale, was utilized to systematically
evaluate this adverse effect in the current study (Johns, 1991; Velligan
et al., 2006; Kane and Sharif, 2008; Dibonaventura et al., 2012). Treat-
ment with both the 80 mg/d and 160 mg/d doses of lurasidone were
associated with endpoint reduction in the Epworth Sleepiness Scale
total score (improvement in somnolence), while treatment with
QXR-600 mg was associated with a signiﬁcant increase in daytime
somnolence compared with both doses of lurasidone, and with place-
bo. The afﬁnity of selected atypical antipsychotics for the H1 receptor
(e.g., clozapine, olanzapine, quetiapine, risperidone), appears to be
correlated with risk of somnolence. In contrast, lurasidone has been
reported to lack afﬁnity for the H1 receptor (Ishibashi et al., 2010). In
the current trial, study medication was taken in the evening, which
may have limited the incidence of daytime somnolence for both drugs.
Several potential study limitations should be noted. First, use of a
ﬁxed-dose design facilitated assessment of dose–response effects, but
may have reduced the ability of the investigator to optimize the toler-
ability of study drug. Despite this potential limitation, both lurasidone
and QXR-600 mg were well-tolerated, with a low incidence of ad-
verse events, and a low attrition rate. Second, in order to optimally
evaluate treatment effect, study entry criteria required patients to
be experiencing an acute exacerbation of psychosis, while limiting
medical comorbidity and use of concomitant medications. This may
have reduced the generalizability of the study results.
In summary, the results of the current study demonstrated that
lurasidone 80 mg and 160 mg, administered once daily in the evening
with food, were efﬁcacious treatments for subjects with an acute
exacerbation of chronic schizophrenia. Study ﬁndings suggest that
lurasidone 160 mg may be associated with some efﬁcacy advantages
over the 80 mg dose. Therewere no dose-related effects for lurasidone
on weight, metabolic parameters, akathisia or other movement dis-
orders, or QTc interval. Differences in the beneﬁt-risk proﬁle of
lurasidone and QXR-600 mg during the current short-term trial
were primarily safety related. Treatment with QXR-600 mg was asso-
ciated with signiﬁcant short-term effects on weight, other metabolic
parameters and daytime somnolence compared with lurasidone, and
less effect on prolactin. The current results suggest that the lurasidone
160 mg dose may be appropriate for patients with schizophrenia
who require additional efﬁcacy beneﬁt beyond that obtained at
lower doses, but may be associated with a slightly higher incidence
of selected adverse events in some patients, including an increase in
prolactin, somnolence and Parkinsonism but not akathisia.
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